Measles & Rubella Virus Vaccine Live U.S.P 10 doses

Indications

• Urea cycle disorders
• Hyperammonaemia types I and II
• Citrullinaemia
• Arginosuccinic aciduria
• Deficiency of N-acetyl glutamate synthetase
• Acute hyperammonaemia in carbamylphosphate synthetase deficiency
• Acute hyperammonaemia in ornithine transcarbamylase deficiency

Dosage

Children: Neonate: 100–300 mg/kg daily in 3–4 divided doses; Child (body-weight up to 40 kg): 6 mg/kg/hour; Child (body-weight 40 kg and above): 4 mg/kg/hour.

Adults: Refer to BNF for specific dosing based on condition; typically administered as 5–50 mg/kg twice daily, adjusted according to plasma ammonia concentration.

Mechanism of action

Arginine serves as a substrate for the synthesis of nitric oxide (NO), a crucial signaling molecule, and contributes to the urea cycle, facilitating the detoxification of ammonia in the liver.

Pharmacodynamics

As a precursor for nitric oxide, arginine plays a vital role in vasodilation and modulating blood flow. It also aids in protein synthesis and supports metabolic processes in the body.

Pharmacokinetics

Arginine is absorbed from the gastrointestinal tract and is distributed throughout the body. It undergoes hepatic metabolism, primarily via the urea cycle, and its half-life is influenced by renal function.

Pregnancy

Use only if clearly needed; consult specialist.

Breast-feeding

Use with caution; benefits should outweigh risks.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• L-Arginine 500 mg tablets
• L-Arginine 1 gram tablets
• L-Arginine powder for solution
• L-Arginine 500 mg capsules
• L-Arginine 21% concentrate for solution for infusion

Indications

• Electrolyte replacement
• Volume expansion in hypovolemic patients
• Management of hyponatremia
• Support in intravenous fluid therapy

Dosage

Children: Refer to the BNF for Children for appropriate dosing in paediatric patients, as dosages may vary based on the formulation and clinical condition.

Adults: Refer to specific product information or clinical guidelines for dosage recommendations, as disodium is often part of combination products.

Mechanism of action

Disodium compounds often function by providing sodium ions that are essential for various physiological processes. Sodium ions play a critical role in maintaining osmotic balance, nerve impulse transmission, and muscle contraction. In the context of intravenous solutions, disodium helps to restore electrolyte balance in patients.

Pharmacodynamics

The pharmacodynamics of disodium is primarily related to its role in electrolyte balance and fluid homeostasis. Sodium ions are vital for the function of excitable tissues, including neurons and muscle cells. Changes in sodium levels can affect blood pressure, hydration status, and overall cellular function.

Pharmacokinetics

The pharmacokinetics of disodium compounds depend on their specific formulation and route of administration. When administered intravenously, disodium is rapidly distributed in the extracellular fluid, where it helps to maintain osmotic pressure. Sodium is primarily excreted by the kidneys, and its levels can be influenced by fluid intake, dietary sodium, and renal function.

Pregnancy

Use with caution. Consult a healthcare provider for specific guidance.

Breast-feeding

Use with caution. Consult a healthcare provider for specific guidance.

Storage

Store at room temperature, away from moisture and direct sunlight.

Indications

• Lead poisoning
• Mercury poisoning
• Calcium overload
• Certain diagnostic procedures involving heavy metals

Dosage

Children: Refer to the BNF for Children for appropriate dosing information tailored for paediatric patients.

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated, considering factors such as the severity of metal poisoning and renal function.

Mechanism of action

Edetate functions by forming stable complexes with divalent and trivalent metal ions, including lead and calcium, through its multiple carboxylate and amine groups. This chelation renders the metals more soluble and promotes their renal excretion, thereby reducing their toxic effects in the body.

Pharmacodynamics

The chelation of metals by edetate decreases the free metal concentration in the bloodstream, which mitigates the toxic effects associated with heavy metal accumulation. The efficacy of edetate in removing metals such as lead has been well documented, and its ability to bind calcium can influence calcium homeostasis in certain clinical scenarios.

Pharmacokinetics

Edetate is administered intravenously, with rapid distribution throughout the extracellular fluid. It is primarily excreted unchanged by the kidneys. The onset of action occurs quickly after administration, and the duration depends on the dose and the patient's renal function. The elimination half-life is approximately 1 hour but may vary based on renal clearance.

Contra-indications

• Hypersensitivity to edetate or any component of the formulation
• Severe renal impairment
• Active bleeding disorders

Adverse effects

• Hypocalcemia
• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Headache
• Rash
• Fever

Interactions

• May enhance the effects of anticoagulants
• Concurrent use with calcium supplements may reduce effectiveness
• May interfere with the absorption of certain medications due to changes in gastrointestinal motility

Precautions

• Use with caution in patients with renal impairment
• Monitor electrolyte levels, particularly calcium, during treatment
• Assess the patient's hydration status before administration

Pregnancy

Limited data on the use of edetate in pregnancy. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised as it is not known whether edetate is excreted in human milk. Weigh the risks and benefits before use.

Storage

Store in a cool, dry place, protected from light. Do not freeze.

Formulations

• Edetate disodium injection
• Edetate calcium disodium injection

Indications

• Nutritional supplementation
• Support for skin health
• Management of inflammatory conditions
• Cognitive function enhancement
• Cardiovascular health support

Dosage

Children: Refer to specific product guidelines as doses may vary by formulation and manufacturer.

Adults: Refer to specific product guidelines as doses may vary by formulation and manufacturer.

Mechanism of action

The essential fatty acids in Essensial, such as omega-3 and omega-6 fatty acids, are incorporated into cell membranes, influencing membrane fluidity and function. They serve as precursors for bioactive lipids that modulate inflammatory pathways and cell signaling, thereby promoting cardiovascular health and reducing inflammation.

Pharmacodynamics

Essential fatty acids exert their effects by being metabolized into eicosanoids, which are signaling molecules involved in inflammation and immune responses. Omega-3 fatty acids, for example, are known to produce anti-inflammatory eicosanoids, while omega-6 fatty acids can produce pro-inflammatory mediators. The balance between these fatty acids is vital for maintaining health and preventing chronic diseases.

Pharmacokinetics

After oral administration, essential fatty acids are absorbed in the intestine and transported via the lymphatic system into the bloodstream. They are then integrated into cellular membranes or metabolized into various derivatives. The half-life of these fatty acids can vary, but they are generally incorporated into body tissues, where they can exert their effects over time.

Pregnancy

Consult a healthcare professional before use. The safety of this drug in pregnancy has not been established.

Breast-feeding

Consult a healthcare professional before use. The safety of this drug in breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Oxidative stress-related conditions
• Inflammatory conditions
• Potential anti-aging applications
• Vascular health enhancement

Dosage

Children: Refer to specific product formulations and guidelines, as dosing can vary based on the concentration of hydrogen in the product used.

Adults: Refer to specific product formulations and guidelines, as dosing can vary based on the concentration of hydrogen in the product used.

Mechanism of action

Molecular hydrogen acts primarily as an antioxidant and anti-inflammatory agent. It is believed to exert its beneficial effects through the activation of the Nrf2 pathway, which enhances the expression of antioxidant enzymes and protects cells from oxidative stress. Hydrogen-rich environments have been shown to mitigate the harmful effects of various toxins on human umbilical vein endothelial cells, thereby promoting vascular health and longevity.

Pharmacodynamics

Hydrogen's pharmacodynamic properties are linked to its role as a potent antioxidant, which reduces reactive oxygen species (ROS) and modulates inflammation. It has been documented to counteract cellular senescence in endothelial cells, thereby maintaining vascular integrity and promoting overall health. The long-lasting effects of hydrogen exposure can be observed even after its concentration in the medium has decreased, suggesting a sustained activation of protective cellular pathways.

Pharmacokinetics

Hydrogen is a gaseous molecule that diffuses rapidly across biological membranes. Its absorption and distribution in the body are influenced by the method of administration, with hydrogen-rich water being a common delivery form. Once in the bloodstream, hydrogen is quickly utilized by tissues, and its concentration diminishes rapidly, with a half-life that can vary based on conditions. The elimination of hydrogen primarily occurs via exhalation, making it a non-toxic molecule with a favorable safety profile.

Pregnancy

Hydrogen is generally considered safe during pregnancy, but it is advisable to consult a healthcare provider for specific recommendations.

Breast-feeding

Hydrogen is considered safe during breastfeeding, but as with any substance, it is recommended to discuss with a healthcare provider.

Storage

Hydrogen should be stored in a cool, dry place away from direct sunlight and heat sources, in appropriate gas cylinders designed for compressed gases.

Formulations

• Hydrogen gas (H2)
• Hydrogen-rich water

Mechanism of action

Hydrogenphosphate acts as a substrate for various enzymatic reactions where phosphate groups are transferred or incorporated into organic molecules. It is involved in metabolic pathways such as nicotine biosynthesis and NAD/NADH cycling, facilitating biochemical reactions that are vital for cellular function.

Pharmacodynamics

Hydrogenphosphate is crucial for maintaining cellular homeostasis. It regulates acid-base balance and is involved in energy metabolism. The phosphate groups it provides are integral to the structure and function of ATP, which is the primary energy currency of the cell. Additionally, hydrogenphosphate influences signal transduction pathways through phosphorylation and dephosphorylation processes.

Pharmacokinetics

Hydrogenphosphate is readily absorbed in the gastrointestinal tract and distributed throughout the body. Its elimination primarily occurs through renal excretion, where it is filtered and reabsorbed by the kidneys. The balance of hydrogenphosphate levels is tightly regulated by various physiological mechanisms to ensure proper metabolic function.

Pregnancy

There is limited information regarding the safety of hydrogenphosphate in pregnancy. Consult relevant guidelines and consider potential risks versus benefits.

Breast-feeding

Data on the excretion of hydrogenphosphate in human milk are not available. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight. Ensure containers are tightly closed.

Indications

• Nutritional support in malnourished patients
• Post-operative recovery
• Management of malabsorption syndromes
• Support in conditions requiring enhanced protein intake

Dosage

Children: Refer to the BNF for Children for dosing recommendations.

Adults: Refer to specific formulations and BNF guidelines for appropriate dosing.

Mechanism of action

Hydrolysates increase the availability of amino acids and peptides for absorption in the intestines. The smaller size of these molecules compared to whole proteins facilitates their transport across the intestinal wall, allowing for quicker and more effective utilization by the body. This mechanism is particularly beneficial in patients with compromised digestive capabilities.

Pharmacodynamics

The pharmacodynamic effects of hydrolysates involve the supply of essential and non-essential amino acids, which are crucial for various metabolic processes, including protein synthesis, neurotransmitter production, and immune function. The rapid absorption of these peptides can lead to quicker recovery times in malnourished individuals or those undergoing surgical recovery.

Pharmacokinetics

Hydrolysates are rapidly absorbed in the gastrointestinal tract, with peak plasma concentrations occurring shortly after ingestion. The bioavailability of amino acids from hydrolysates is generally higher than that of intact proteins due to their smaller molecular size. The metabolism of amino acids occurs primarily in the liver, where they can be utilized for energy production or incorporated into new proteins. The elimination of amino acids happens through renal pathways, with excess being excreted in urine.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known if hydrolysate is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Indications

• Nutritional supplementation
• Support for muscle growth and recovery
• Infant nutrition in formulas
• Immune system support

Dosage

Children: Refer to specific product guidelines or consult a healthcare professional for appropriate dosing.

Adults: Refer to specific product guidelines or consult a healthcare professional for appropriate dosing.

Mechanism of action

Lactalbumin provides essential amino acids that are crucial for protein synthesis in the body. It is rapidly absorbed and utilized by muscle tissues, contributing to muscle repair and growth. The presence of certain bioactive peptides in lactalbumin may also enhance immune response and promote overall health.

Pharmacodynamics

Lactalbumin has been shown to have various beneficial effects on the body, including enhancing muscle protein synthesis, improving recovery from exercise, and supporting immune health. The amino acids, particularly branched-chain amino acids, play a significant role in stimulating muscle protein synthesis and reducing muscle breakdown.

Pharmacokinetics

Lactalbumin is absorbed in the gastrointestinal tract following ingestion. The amino acids are then distributed throughout the body and utilized for various metabolic processes, including protein synthesis. The half-life and clearance rates vary depending on the individual's metabolic state and activity levels.

Adverse effects

• Allergic reactions
• Gastrointestinal disturbances
• Nausea
• Vomiting

Precautions

• Use with caution in patients with known allergies to milk or milk products
• Monitor for allergic reactions in sensitive individuals

Pregnancy

Lactalbumin is generally considered safe during pregnancy, but it is advisable to consult a healthcare professional before use.

Breast-feeding

Lactalbumin can be used during breastfeeding; however, any concerns regarding allergies should be discussed with a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powder
• Liquid

Indications

• Prevention of measles through vaccination
• Management of measles infection in symptomatic patients
• Prevention of complications associated with measles infection

Dosage

Children: Refer to local vaccination guidelines for measles immunization recommendations.

Adults: Refer to local vaccination guidelines for measles immunization recommendations.

Mechanism of action

The measles virus enters host cells through the interaction of its hemagglutinin (H) protein with the CD150 (SLAM) receptor on the surface of immune cells. Following entry, the viral RNA is released into the cytoplasm, leading to the replication of the viral genome and the production of viral proteins. The newly formed virions are then released from the host cell, allowing the virus to spread to adjacent cells.

Pharmacodynamics

Measles virus infection leads to a robust immune response, resulting in the activation of both humoral and cellular immunity. The disease is characterized by an initial immune suppression, followed by a strong immune response that typically clears the virus. However, this immune suppression can leave the host vulnerable to secondary infections.

Pharmacokinetics

As a virus, measles does not have pharmacokinetic properties in the traditional sense, as it does not undergo metabolism or elimination like a drug. Instead, the virus's lifecycle involves attachment, entry, replication, and release from host cells. The duration of viral shedding can last for several days before the appearance of the rash.

Contra-indications

• Severe allergic reaction to a previous dose of measles vaccine
• Severe immunodeficiency (e.g., in patients with HIV/AIDS, or those receiving high-dose immunosuppressive therapy)
• Pregnancy (in certain live vaccines, including measles)

Adverse effects

• Fever
• Rash
• Diarrhea
• Otitis media
• Pneumonia
• Encephalitis (rare)

Interactions

• Live attenuated vaccines should not be administered simultaneously with immunoglobulins (e.g., anti-rabies serum) as they may interfere with the immune response
• Corticosteroids may reduce the immune response to the vaccine

Precautions

• Assess for history of severe allergic reactions
• Monitor for signs of respiratory distress in patients with a history of asthma or other respiratory conditions
• Consider vaccination timing in patients with recent blood transfusions or immunoglobulin administration

Pregnancy

Measles vaccination is contraindicated during pregnancy due to potential harm to the fetus. Women should be advised to avoid pregnancy for a month after receiving the vaccine.

Breast-feeding

Measles vaccination is generally considered safe during breastfeeding, though it is recommended to consult healthcare providers for individual cases.

Storage

Store in a refrigerator at 2°C to 8°C, do not freeze. Protect from light.

Formulations

• Measles vaccine (live attenuated)
• Combination measles, mumps, rubella (MMR) vaccine

Dosage

Children: Refer to specific product guidelines as dosage will depend on the type of medium and its intended application.

Adults: Refer to specific product guidelines as dosage will depend on the type of medium and its intended application.

Mechanism of action

The mechanism of action for a medium can vary greatly depending on the specific medium being referenced. Generally, media serve to maintain the stability and viability of cells or organisms during culture, enabling metabolic processes to occur. For instance, nutrient media provide essential nutrients, while selective media may inhibit the growth of certain organisms while promoting others.

Pharmacodynamics

Pharmacodynamics is largely dependent on the type of medium used and its components. In tissue cultures, the medium can influence cell growth, differentiation, and physiological responses. The interactions of cells with their environment are critical for cellular signaling and function.

Pharmacokinetics

Pharmacokinetics is not typically applicable to media in the same way it is for active drugs. However, the absorption and distribution of substances within a medium can affect how well the active ingredients are delivered or how organisms interact with the medium. Factors such as pH, osmolarity, and nutrient concentration can all influence these processes.

Pregnancy

Consult a healthcare provider before use, as the safety of medium in pregnancy has not been established.

Breast-feeding

Consult a healthcare provider before use, as it is unknown whether medium passes into breast milk.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Sepsis
• Pneumonia
• Urinary tract infections
• Bacterial endocarditis
• Intra-abdominal infections

Dosage

Children: Refer to BNF for Children for appropriate dosing based on the child's age, weight, and clinical condition.

Adults: Refer to specific clinical guidelines or BNF for appropriate dosing based on the infection being treated, renal function, and patient-specific factors.

Mechanism of action

Minim binds to the 30S subunit of the bacterial ribosome, interfering with the initiation complex of protein synthesis. This binding disrupts the decoding site of the ribosome, causing misreading of mRNA and ultimately inhibiting the synthesis of proteins essential for bacterial growth and replication.

Pharmacodynamics

Minim exhibits concentration-dependent killing, meaning that higher drug concentrations result in a more significant antibacterial effect. It is particularly potent against aerobic gram-negative bacteria. The drug's efficacy is enhanced by its ability to penetrate bacterial cells and bind effectively to ribosomal targets, leading to rapid bactericidal activity.

Pharmacokinetics

Minim is primarily administered via intravenous or intramuscular routes, as it is poorly absorbed from the gastrointestinal tract. It has a volume of distribution that suggests good tissue penetration. The drug is primarily eliminated by the kidneys, with renal function significantly affecting its clearance. Serum half-life is typically prolonged in patients with impaired kidney function, necessitating dose adjustments in such populations.

Contra-indications

• Known hypersensitivity to minimum or any of its components
• Severe hepatic impairment
• Pregnancy (unless the benefits outweigh the risks)

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Headache
• Dizziness
• Fatigue
• Hypersensitivity reactions
• Liver enzyme elevation

Interactions

• Caution with concomitant use of other hepatotoxic agents
• Increased risk of bleeding if used with anticoagulants
• May reduce the effectiveness of certain antiepileptic drugs

Precautions

• Use with caution in patients with pre-existing liver disease
• Monitor liver function tests during treatment
• Assess for potential drug interactions prior to initiating therapy

Pregnancy

Limited data available. Use only if the benefits outweigh the risks.

Breast-feeding

Use with caution. Monitor infant for potential side effects.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Formulations

• Oral tablets
• Injectable solution
• Topical cream

Indications

• Prevention of mumps through vaccination
• Management of mumps infection
• Monitoring for complications such as orchitis or meningitis

Dosage

Children: Refer to the BNF for Children for specific vaccination schedules and dosage recommendations related to the MMR vaccine.

Adults: Refer to the specific guidelines for vaccination, typically the MMR vaccine is administered as a two-dose series, with the first dose given at 1 year of age and a second dose at 4 to 6 years of age. Further details should be checked in the relevant vaccination schedule.

Mechanism of action

The mumps virus enters host cells by binding to sialic acid receptors on the surface of the cells. Once inside, the virus releases its RNA genome, leading to the production of viral proteins and replication of the viral genome. The newly formed viral particles are then released from the host cell, allowing for further infection of adjacent cells.

Pharmacodynamics

Mumps primarily affects the salivary glands but can also impact other organs such as the testes, ovaries, pancreas, and central nervous system. The immune response to the infection typically involves the activation of T cells and the production of antibodies, which help to clear the virus from the body. The severity of the disease can vary, with some individuals experiencing mild symptoms while others may develop complications such as orchitis or meningitis.

Pharmacokinetics

The pharmacokinetics of the mumps virus is not applicable in the traditional sense as it is a viral infection. However, the incubation period for mumps is typically 16 to 18 days, with the virus being contagious from approximately three days before to five days after the onset of parotitis. The immune response develops over a period of weeks, leading to long-lasting immunity in most cases post-infection or vaccination.

Adverse effects

• Fever
• Headache
• Muscle pain
• Swelling of the salivary glands
• Orchitis (inflammation of the testes)
• Oophoritis (inflammation of the ovaries)
• Meningitis
• Encephalitis

Precautions

• Individuals with weakened immune systems should be monitored closely.
• Vaccination may be less effective in those with specific conditions affecting the immune response.

Pregnancy

Mumps vaccination is generally avoided during pregnancy unless the benefits outweigh the risks, as the effects of the vaccine on fetal development are not fully established.

Breast-feeding

Vaccination is not contraindicated during breastfeeding, but consultation with a healthcare provider is recommended.

Storage

Store at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.

Formulations

• Live attenuated mumps virus vaccine

Indications

• Prevention of rubella infection through vaccination
• Screening and management of congenital rubella syndrome in newborns
• Public health measures to control rubella outbreaks

Dosage

Children: For vaccination, the MMR vaccine is typically administered to children at ages 12-15 months and a second dose at 4-6 years.

Adults: For vaccination, a single dose of the MMR (measles, mumps, rubella) vaccine is recommended for adults who have not been previously vaccinated or who lack immunity.

Mechanism of action

The rubella virus enters the body through the respiratory tract and replicates in the nasopharynx and regional lymph nodes. It then spreads to the bloodstream and other tissues, leading to a systemic infection. The immune response to the virus, including the production of IgM and IgG antibodies, is responsible for the clinical manifestations of the disease.

Pharmacodynamics

The rubella virus is a single-stranded RNA virus that belongs to the Togaviridae family. After infection, the virus induces an immune response that includes both humoral and cellular immunity. The resulting antibody production provides long-lasting immunity to reinfection. The clinical symptoms, such as fever and rash, are primarily due to the immune response rather than direct viral damage.

Pharmacokinetics

The incubation period for rubella is typically 14 to 21 days. The virus is present in the nasopharynx and urine. The immune response develops within a few days of infection, leading to the production of antibodies. The presence of IgM antibodies indicates an acute infection, while IgG antibodies indicate past infection or vaccination. The virus is usually eliminated from the body within a few weeks, but immunity persists for life following infection or vaccination.

Contra-indications

• Hypersensitivity to rubella vaccine components
• Pregnancy in women who have not been vaccinated or infected previously

Adverse effects

• Mild fever
• Rash
• Joint pain
• Lymphadenopathy
• Transient thrombocytopenia

Interactions

• Live attenuated vaccines may interfere with each other
• Immunosuppressive therapies may reduce vaccine efficacy

Precautions

• History of anaphylactic reactions to neomycin or gelatin
• Individuals with severe immunodeficiency should not receive live vaccines
• Pregnant women should avoid conception for at least one month after vaccination

Pregnancy

Rubella vaccination is contraindicated during pregnancy due to potential harm to the fetus. Women are advised to receive the vaccine before conception.

Breast-feeding

Rubella vaccination is considered safe during breastfeeding.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Live attenuated rubella vaccine

Indications

• Buffering agent in biochemical and molecular biology applications
• Used in protein electrophoresis
• Stabilizing pH in various laboratory experiments

Dosage

Children: Refer to specific protocols for laboratory use, as tricine is not typically administered as a medication.

Adults: Refer to specific protocols for laboratory use, as tricine is not typically administered as a medication.

Mechanism of action

Tricine acts as a buffering agent, helping to maintain pH stability in biological systems. It does this by accepting and donating protons (H+) depending on the pH of the environment, thereby minimizing fluctuations in acidity or alkalinity during biochemical reactions.

Pharmacodynamics

Tricine functions primarily as a buffering agent, which is crucial in maintaining the structural integrity and function of biomolecules in various biochemical assays. Its zwitterionic nature allows it to stabilize pH in physiological ranges, ensuring optimal conditions for enzymatic reactions and other cellular processes.

Pharmacokinetics

Information on the pharmacokinetics of tricine, including absorption, distribution, metabolism, and excretion, is not widely documented, as it is primarily used in vitro rather than as a pharmaceutical agent. It is expected to be well tolerated in biological systems, given its compatibility with biological molecules.

Pregnancy

Tricine is not classified in pregnancy categories by the FDA. Consult relevant guidelines for use during pregnancy.

Breast-feeding

Tricine is generally considered safe during breastfeeding, but it is advisable to consult a healthcare professional.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• {'formulation': 'Tricine solution', 'details': 'Used as a buffer in various biochemical applications.'}

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.

Mechanism of action

Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production.

Pharmacodynamics

Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair.

Mechanism of action

Substantial evidence indicates that molecular hydrogen (H2) has beneficial vascular effects because of its antioxidant and/or anti-inflammatory effects. Thus, hydrogen-rich water may prove to be an effective anti-aging drink. This study examined the effects of H2 on endothelial senescence and clarified the mechanisms involved. Hydrogen-rich medium was produced by a high-purity hydrogen gas generator. Human umbilical vein endothelial cells (HUVECs) were incubated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) for various time periods in normal or hydrogen-rich medium. The baseline H2concentration in hydrogen-rich medium was 0.55 +/- 0.07 mmol/L. This concentration gradually decreased, and H2 was almost undetectable in medium after 12 hr. At 24 hr after TCDD exposure, HUVECs treated with TCDD exhibited increased 8OHdG and acetyl-p53 expression, decreased nicotinamide adenine dinucleotide (NAD(+))/NADH ratio, impaired Sirt1 activity, and enhanced senescence-associated beta-galactosidase. However, HUVECs incubated in hydrogen-rich medium did not exhibit these TCDD-induced changes accompanying Nrf2 activation, which was observed even after H2 was undetectable in the medium. Chrysin, an inhibitor of Nrf2, abolished the protective effects of H2 on HUVECs. H2 has long-lasting antioxidant and anti-aging effects on vascular endothelial cells through the Nrf2 pathway, even after transient exposure to H2. Hydrogen-rich water may thus be a functional drink that increases longevity. /Hydrogen-rich water/ Amyloid beta (Abeta) peptides are identified /as a/ cause of neurodegenerative diseases such as Alzheimer's disease (AD). Previous evidence suggests Abeta-induced neurotoxicity is linked to the stimulation of reactive oxygen species (ROS) production. The accumulation of Abeta-induced ROS leads to increased mitochondrial dysfunction and triggers apoptotic cell death. This suggests antioxidant therapies may be beneficial for preventing ROS-related diseases such as AD. Recently, hydrogen-rich water (HRW) has been proven effective in treating oxidative stress-induced disorders because of its ROS-scavenging abilities. However, the precise molecular mechanisms whereby HRW prevents neuronal death are still unclear. In the present study, we evaluated the putative pathways by which HRW protects against Abeta-induced cytotoxicity /in SK-N-MC cells/. Our results indicated that HRW directly counteracts oxidative damage by neutralizing excessive ROS, leading to the alleviation of Abeta-induced cell death. In addition, HRW also stimulated AMP-activated protein kinase (AMPK) in a sirtuin 1 (Sirt1)-dependent pathway, which upregulates forkhead box protein O3a (FoxO3a) downstream antioxidant response and diminishes Abeta-induced mitochondrial potential loss and oxidative stress. Taken together, our findings suggest that HRW may have potential therapeutic value to inhibit Abeta-induced neurotoxicity. /Hydrogen-rich water/ The NLRP3 inflammasome, an intracellular multi-protein complex controlling the maturation of cytokine interleukin-1beta, plays an important role in lipopolysaccharide (LPS)-induced inflammatory cascades. Recently, the production of mitochondrial reactive oxygen species (mtROS) in macrophages stimulated with LPS has been suggested to act as a trigger during the process of NLRP3 inflammasome activation that can be blocked by some mitochondria-targeted antioxidants. Known as a ROS scavenger, molecular hydrogen (H2) has been shown to possess therapeutic benefit on LPS-induced inflammatory damage in many animal experiments. Due to the unique molecular structure, H2 can easily target the mitochondria, suggesting that H2 is a potential antagonist of mtROS-dependent NLRP3 inflammasome activation. Here we have showed that, in mouse macrophages, H2 exhibited substantial inhibitory activity against LPS-initiated NLRP3 inflammasome activation by scavenging mtROS. Moreover, the elimination of mtROS by H2 resultantly inhibited mtROS-mediated NLRP3 deubi